CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...
The year-end report for the period January - December 2024 is attached to this press release and is available on the company's website www.intervacc.se /investors/reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback